Catalent and Bhami Research Laboratory (BRL) entered into a licensing agreement that will provide Catalent with access to BRL’s formulation technology to help enable the subcutaneous delivery of high-concentration biologic therapies. Under the agreement, Catalent is authorized to collaborate with its customers to evaluate BRL’s formulation technology to reduce viscosity and deliver high-concentration biologics. The technology is applicable to a wide range of monoclonal antibodies and fusio...